Idiopathic inflammatory myopathies: Current trends in pathogenesis, clinical features, and up-to-date treatment recommendations

Mayo Clinic Proceedings

Volumn 88, Issue 1, 2013, Pages 83-105

  Ernste, Floranne C ^a   Reed, Ann M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; BETA1A INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CHLOROQUINE; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; FOLIC ACID; FOLINIC ACID; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXANDROLONE; PLACEBO; PREDNISONE; PROBENECID; RITUXIMAB; SODIUM THIOSULFATE; TACROLIMUS; UNINDEXED DRUG; WARFARIN;

ALGORITHM; AMYOPATHIC DERMATOMYOSITIS; ANXIETY DISORDER; AVASCULAR NECROSIS; CALCINOSIS; CATARACT; CLINICAL FEATURE; COMPRESSION FRACTURE; CYTOPENIA; DAILY LIFE ACTIVITY; DEPRESSION; DERMATOMYOSITIS; DIABETES MELLITUS; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG FEVER; DRUG MEGADOSE; DYSLIPIDEMIA; ELASTOGRAPHY; ELECTROMYOGRAM; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOMYOPATHIC DERMATOMYOSITIS; IMMUNE MEDIATED NECROTIZING MYOPATHY; IMMUNOGLOBULIN A DEFICIENCY; INCLUSION BODY MYOSITIS; INFECTION; INFECTION RISK; INFERTILITY; JUVENILE DERMATOMYOSITIS; KIDNEY FAILURE; LIVER TOXICITY; LOOSE FECES; LUNG DISEASE; MOOD DISORDER; MUSCLE BIOPSY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOPATHY; MYOSITIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PNEUMOCYSTIS PNEUMONIA; POLYMYOSITIS; PREMATURE OVARIAN FAILURE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; QUESTIONNAIRE; RETINA DISEASE; REVIEW; SECONDARY PREVENTION; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; STRIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN;

EID: 84872909876     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.10.017     Document Type: Review

References (184)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-347.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-407.
3. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol. 1989;20(3):224-231.
4. Dalakas MC, Sivakumar K. The immunopathologic and inflammatory differences between dermatomyositis, polymyositis and sporadic inclusion body myositis. Curr Opin Neurol. 1996;9(3):235-239.
5. Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res Nerv Ment Dis. 1990;68:141-157.
6. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol. 1986;17(7):704-721.
7. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies, IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol. 1988;23(2):168-173.
8. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies, III: immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol. 1986;19(2):112-125.
9. Greenberg SA. Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications. Neurology. 2007;69(21):2008-2019.
10. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986;314(6):329-334.
11. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990;27(4):343-356.
12. Crowe WE, Bove KE, Levinson JE, Hilton PK. Clinical and pathogenetic implications of histopathology in childhood polydermatomyositis. Arthritis Rheum. 1982;25(2):126-139.
13. Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 1997;23(3):619-655.
14. Lorenzoni PJ, Scola RH, Kay CS, Prevedello PG, Espíndola G, Werneck LC. Idiopathic inflammatory myopathies in childhood: a brief review of 27 cases. Pediatr Neurol. 2011;45(1):17-22.
15. Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201-2212.
16. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology. 1991;41(6):936-939.
17. Bronner IM, Hoogendijk JE, Wintzen AR, et al. Necrotising myopathy, an unusual presentation of a steroid-responsive myopathy. J Neurol. 2003;250(4):480-485.
18. Liang C, Needham M. Necrotizing autoimmune myopathy. Curr Opin Rheumatol. 2011;23(6):612-619.
19. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve. 2010;41(2):185-190.
20. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immunemediated necrotizing myopathy. Arthritis Rheum. 2010;62(9):2757-2766.
21. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti- HMG-CoA reductase-associated autoimmune myopathy [published online ahead of print August 29, 2012]. Arthritis Rheum. http://dx.doi.org/10.1002/art.34673.
22. Lotz BP, Engel AG, Nishino H, Stevens JC, Litchy WJ. Inclusion body myositis: observations in 40 patients. Brain. 1989; 112(pt 3):727-747.
23. Weihl CC, Pestronk A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol. 2010;23(5):482-488.
24. Karpati G, O'Ferrall EK. Sporadic inclusion body myositis: pathogenic considerations. Ann Neurol. 2009;65(1):7-11.
25. Salajegheh M, Pinkus JL, Nazareno R, Amato AA, Parker KC, Greenberg SA. Nature of "tau" immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve. 2009; 40(4):520-528.
26. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705-713.
27. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositisspecific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991;70(6):360-374.
28. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford). 2009;48(6):607-612.
29. Hengstman GJ, van Brenk L, Vree Egberts WT, et al. High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. J Neurol. 2005;252(5):534-537.
30. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep. 2006;8(3):196-203.
31. Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-g antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010;49(9):1726-1733.
32. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009;60(7):2193-2200.
33. Gunawardena H, Wedderburn LR, Chinoy H, et al Juvenile Dermatomyositis Research Group, UK and Ireland. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009;60(6):1807- 1814.
34. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13(2):209.
35. Bilgic H, Ytterberg SR, Amin S, et al. Interleukin-6 and type 1 interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 2009;60(11):3436-3446.
36. Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1-2):59-68.
37. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-a/be mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664-678.
38. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain. 2005;128(pt 8):1887-1896.
39. Reed AM, Peterson E, Bilgic H, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course [published online ahead of print August 8, 2012]. Arthritis Rheum. http://dx.doi.org/10.1002/art.34659.
40. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 2002; 47(6):614-622.
41. Selva-O'Callaghan A, Labrador-Horillo M, Muñoz-Gall X, et al. Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients. Lupus. 2005;14(7):534-542.
42. Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford Jr. Dysphagia in inflammatory myopathy: clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82(4):441-447.
43. Yazici Y, Kagen LJ. Cardiac involvement in myositis. Curr Opin Rheumatol. 2002;14(6):663-665.
44. Gupta R, Wayangankar SA, Targoff IN, Hennebry TA. Clinical cardiac involvement in idiopathic inflammatory myopathies: a systematic review. Int J Cardiol. 2011;148(3):261-270.
45. Dalakas MC. Pathophysiology of inflammatory and autoimmune myopathies. Presse Med. 2011;40(4, pt 2):e237-e247.
46. Ruperto N, Ravelli A, Pistorio A, et al Paediatric Rheumatology International Trials Organisation (PRINTO); Pediatric Rheumatology Collaborative Study Group (PRCSG). The provisional Paediatric Rheumatology International Trials Organisation/ American College of Rheumatology/European League Against Rheumatism disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4-13.
47. Brown VE, Pilkington CA, Feldman BM, Davidson JE; Network for Juvenile Dermatomyositis, Paediatric Rheumatology European Society (PReS). An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM). Rheumatology (Oxford). 2006;45(8):990-993.
48. Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis. 2003;62(5):444-449.
49. Constantin T, Ponyi A,Orbán I, et al. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungaryd clinical characteristics and disease course of 44 patients with juvenile dermatomyositis. Autoimmunity. 2006;39(3):223-232.
50. Spencer CH, Hanson V, Singsen BH, Bernstein BH, Kornreich HK, King KK. Course of treated juvenile dermatomyositis. J Pediatr. 1984;105(3):399-408.
51. Sterba G, Rodriguez C, Sifontes S, Vigilanza P. Macrophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis [letter]. J Rheum. 2004;31(5):1014-1015.
52. Shulman AI, Punaro M. Critical care of the pediatric patient with rheumatic disease. Curr Opin Pediatr. 2011;23(3):263-268.
53. Gattorno M, Piccini A, Lasigliè D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58(5):1505-1515.
54. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis: a review. J Invest Dermatol. 1993;100(1):124S-127S.
55. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613.
56. Suda T, Fujisawa T, Enomoto N, et al. Interstitial lung diseases associated with amyopathic dermatomyositis. Eur Respir J. 2006;28(5):1005-1012.
57. Bendewald MJ, Wetter DA, Li X, Davis MP. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30.
58. Reed AM, Ytterberg SR. Genetic and environmental risk factors for idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):891-916.
59. Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995;44(3):131-135.
60. Shamim EA, Rider LG, Miller FW. Update on the genetics of the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2000;12(6):482-491.
61. Pachman LM, Liotta-Davis MR, Hong DK, et al. TNFalpha- 308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications. Arthritis Rheum. 2000; 43(10):2368-2377.
62. Christensen ML, Pachman LM, Schneiderman R, Patel DC, Friedman JM. Prevalence of Coxsackie B virus antibodies in patients with juvenile dermatomyositis. Arthritis Rheum. 1986; 29(11):1365-1370.
63. Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR; Juvenile Dermatomyositis Research Group (UK and Ireland). MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004;31(3):605-609.
64. López de Padilla CM, Vallejo AN, McNallan KT, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum. 2007;56(5):1658-1668.
65. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005;23:275-306.
66. López de Padilla CM, Vallejo AN, Lacomis D, McNallen K, Reed AM. Extranodal lymphoid microstructures in inflamed muscle and disease severity of new-onset juvenile dermatomyositis. Arthritis Rheum. 2009;60(4):1160-1172.
67. Swiecki M, Colonna M. Accumulation of plasmacytoid DC: roles in disease pathogenesis and targets for immunotherapy. Eur J Immunol. 2010;40(8):2094-2098.
68. Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40(5):865-874.
69. Liprandi A, Bartoli C, Figarella-Branger D, Pellissier JF, Lepidi H. Local expression of monocyte chemoattractant protein-1 (MCP-1) in idiopathic inflammatory myopathies. Acta Neuropathol. 1999;97(6):642-648.
70. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21(6):610-616.
71. Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 2009;60(8):2499-2504.
72. Benveniste O, Drouot L, Jouen F, et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum. 2011;63(7):1961-1971.
73. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher- Stine L. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken). 2010;62(9):1328-1334.
74. Targoff IN, Mamyrova G, Trieu EP, et al Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006;54(11):3682-3689.
75. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis. 2007; 66(10):1345-1349.
76. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56(9):3112-3124.
77. Rider LG, Miller FW, Targoff IN, et al. A broadened spectrum of juvenile myositis: myositis-specific autoantibodies in children. Arthritis Rheum. 1994;37(10):1534-1538.
78. Wedderburn LR, McHugh NJ, Chinoy H, et al Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford). 2007;46(12):1786-1791.
79. Feldman BM, Reichlin M, Laxer RM, Targoff IN, Stein LD, Silverman ED. Clinical significance of specific autoantibodies in juvenile dermatomyositis. J Rheumatol. 1996;23(10):1794-1797.
80. Rouster-Stevens KA, Pachman LM. Autoantibody to signal recognition particle in African American girls with juvenile polymyositis. J Rheumatol. 2008;35(5):927-929.
81. Benveniste O, Romero NB. Myositis or dystrophy? Traps and pitfalls. Presse Med. 2011;40(4, pt 2):e249-e255.
82. Emery AE. The muscular dystrophies. Lancet. 2002;359(9307):687-695.
83. Ray PN, Belfall B, Duff C, et al. Cloning of the breakpoint of an X; 21 translocation associated with Duchenne muscular dystrophy. Nature. 1985-1986;318(6047):672-675.
84. Reichmann H, Vogler L, Seibel P. Ragged red or ragged blue fibers. Eur Neurol. 1996;36(2):98-102.
85. Zampieri S, Ghirardellow A, Iaccarino L, et al. Polymyositisdermatomyositis and infections. Autoimmunity. 2006;39(3):191-196.
86. Santmyire-Rosenberger B, Dugan EM. Skin involvement in dermatomyositis. Curr Opin Rheumatol. 2003;15(6):714-722.
87. Callen JP. Cutaneous manifestations of dermatomyositis and their management. Curr Rheumatol Rep. 2010;12(3):192-197.
88. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy: a population-based cohort study. Ann Intern Med. 2001;134(12):1087-1095.
89. Zantos D, Zhang Y, Felson D. The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol. 1994;21(10):1855- 1859.
90. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis: a populationbased study. N Engl J Med. 1992;326(6):363-367.
91. Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study. Lancet. 2001;357(9250):96-100.
92. Whitmore SE, Anhalt GJ, Provost TT, et al. Serum CA-125 screening for ovarian cancer in patients with dermatomyositis. Gynecol Oncol. 1997;65(2):241-244.
93. Sherry DD, Haas JE, Milstein JM. Childhood polymyositis as a paraneoplastic phenomenon. Pediatr Neurol. 1993;9(2):155-156.
94. Morris P, Dare J. Juvenile dermatomyositis as a paraneoplastic phenomenon: an update. J Pediatr Hematol Oncol. 2010;32(3):189-191.
95. Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics. 1995;15(3):563-574.
96. Schulze M, Kötter I, Ernemann U, et al. MRI findings in inflammatory muscle diseases and their noninflammatory mimics. AJR Am J Roentgenol. 2009;192(6):1708-1716.
97. Maillard SM, Jones R, Owens C, et al. Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology (Oxford). 2004;43(5):603-608.
98. Park JH, Vansant JP, Kumar NG, et al. Dermatomyositis: correlative MR imaging and P-31 MR spectroscopy for quantitative characterization of inflammatory disease. Radiology. 1990; 177(2):473-479.
99. Hernandez RJ, Sullivan DB, Chenevert TL, Keim DR. MR imaging in children with dermatomyositis: musculoskeletal findings and correlation with clinical and laboratory findings. AJR Am J Roentgenol. 1993;161(2):359-366.
100. Kimball AB, Summers RM, Turner M, et al. Magnetic resonance imaging detection of occult skin and subcutaneous abnormalities in juvenile dermatomyositis: implications for diagnosis and therapy. Arthritis Rheum. 2000;43(8):1866-1873.
101. Davis WR, Halls JE, Offiah AC, Pilkington C, Owens CM, Rosendahl K. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology (Oxford). 2011;50(12):2237-2244.
102. Amarteifio E, Nagel AM, Kauczor HU, Weber MA. Functional imaging in muscular diseases. Insights Imaging. 2011;2(5):609-619.
103. McCullough MB, Domire ZJ, Reed AM, et al. Evaluation of muscles affected by myositis using magnetic resonance elastrography. Muscle Nerve. 2011;43(4):585-590.
104. Winkelman RK, Mulder DW, Lambert EH, Howard FM Jr, Diessner GR. Course of dermatomyositis-polymyositis: comparison of untreated and cortisone-treated patients. Mayo Clinic Proc. 1968;43(8):545-556.
105. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1 beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2000;43(2):336-348.
106. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis: a controlled, clinical trial. Ann Intern Med. 1980;92(3):365-369.
107. Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24(1):45-48.
108. Metzger AL, Bohan A, Goldberg LS, Bluestone R, Pearson CM. Polymyositis and dermatomyositis: combined methotrexate and corticosteroid therapy. Ann Intern Med. 1974;81(2):182-189.
109. Saag KG, Teng GG, Patkar NJ, et al American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-784.
110. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. J Rheumatol. 2000;27(6):1542-1545.
111. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142(1):65-69.
112. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1496-1501.
113. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6, suppl 5): S2-S8.
114. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329(27):1993-2000.
115. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA. 2004;291(19):2367-2375.
116. Barbasso Helmers S, Dastmalchi M, Alexanderson H, et al. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. Ann Rheum Dis. 2007;66(10):1276-1283.
117. Bolosiu HD, Man L, Rednic S. The effect of methylprednisolone pulse therapy in polymyositis/dermatomyositis. Adv Exp Med Biol. 1999;455:349-357.
118. Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46(1):124-130.
119. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601-607.
120. Mahler EA, Blom M, Voermans NC, van Engelen BG, van Riel PL, Vonk MC. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011; 50(12):2206-2213.
121. Oddis CV, Reed AM, Aggarwal R, et al Rituximab in Myositis (RIM) Study Group. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial [published online ahead of print November 2, 2012]. Arthritis Rheum. http://dx.doi. org/10.1002/art.37754.
122. Vulliemoz S, Lurati-Ruiz F, Borruat FX, et al. Favourable outcome of progressive multifocal leucoencephalopathy in two patients with dermatomyositis. J Neurol Neurosurg Psychiatry. 2006;77(9):1079-1082.
123. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043-3051.
124. Vencovský J, Jarosová K, Machácek S, et al. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol. 2000;29(2):95-102.
125. Maeda K, Kimura R, Komuta K, Igarashi T. Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol. 1997;26(1):24-29.
126. Qushmaq KA, Chalmers A, Esdaile JM. Cyclosporine A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review. J Rheumatol. 2000;27(12):2855-2859.
127. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762-1763.
128. Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2010;62(2):219-225.
129. Huber AM, Robinson AB, Reed AM, et al Juvenile Dermatomyositis Subcommittee of the Childhood Arthritis and Rheumatology Research Alliance. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months: results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546-553.
130. Huang JL. Long-term prognosis of patients with juvenile dermatomyositis initially treated with intravenous methylprednisolone pulse therapy. Clin Exp Rheumatol. 1999;17(5):621-624.
131. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000; 19(2):138-141.
132. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis: a review of efficacy and safety. Rheumatology (Oxford). 2004;43(4):491-496.
133. Manlhiot C, Tyrrell PN, Liang L, Atkinson AR, Lau W, Feldman BM. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008; 121(3):e626-e630.
134. Miller LC, Michael AF, Kim Y. Childhood dermatomyositis: clinical course and long-term follow-up. Clin Pediatr (Phila). 1987;26(11):561-566.
135. Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin A therapy in refractory juvenile dermatomyositis: experience and longterm followup of 6 cases. J Rheumatol. 1996;23(8):1424-1427.
136. Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr. 2004;163(9):561-562.
137. Dagher R, Desjonquères M, Duquesne A, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32(3):711-716.
138. Bader-Meunier B, Decaluwe H, Barnerias C, et al Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the French Autoimmunity and Rituximab registry. J Rheumatol. 2011;38(7):1436-1440.
139. Yoshimasu T, Ohtani T, Sakamoto T, Oshima A, Furukawa F. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol. 2002;12(1):50-52.
140. Marmor M, Kellner U, Lai TY, Lyons JS, Mieler WF; American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Opthalmology. 2011;118(2):415-422.
141. Pachman LM, Hayford JR, Chung A, et al. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children. J Rheumatol. 1998;25(6):1198-1204.
142. Balin SJ, Wetter DA, Andersen LK, Davis MD. Calcinosis cutis occurring in association with autoimmune connective tissue disease: the Mayo Clinic experience with 78 patients, 1996- 2009. Arch Dermatol. 2012;148(4):455-462.
143. Arabshahi B, Silverman RA, Jones OY, Rider LG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr. 2012;160(3):520-522.
144. Dalakas MC. Immunotherapy of inflammatory myopathies: practical approach and future prospects. Curr Treat Options Neurol. 2011;13(3):311-323.
145. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997; 48(3):712-716.
146. Walter MC, Lochmüller H, Toepfer M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a doubleblind, placebo-controlled study. J Neurol. 2000;247(1):22-28.
147. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology. 2002;58(2):326.
148. Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-Tlymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61(2):260-262.
149. Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felice KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081-1087.
150. Muscle Study Group. Randomized pilot trial of bINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57(9):1566-1570.
151. published correction appears in Neurology. 2002;58(2):334
152. Muscle Study Group. Randomized pilot trial of high-dose bINF-1a in patients with inclusion body myositis. Neurology. 2004;63(4):718-720.
153. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(pt 6):1536-1544.
154. Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(suppl 11):S118-S157.
155. Miller FW, Rider LG, Chung YL, et al International Myositis Outcome Assessment Collaborative Study Group. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2001;40(11):1262-1273.
156. Huber AM, Dugan EM, Lachenbruch PA, et al Juvenile Dermatomyositis Disease Activity Collaborative Study Group. The Cutaneous Assessment Tool: development and reliability in juvenile idiopathic inflammatory myopathy. Rheumatology (Oxford). 2007;46(10):1606-1611.
157. Huber AM, Dugan EM, Lachenbruch PA, et al Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Preliminary validation and clinical meaning of the Cutaneous Assessment Tool in juvenile dermatomyositis. Arthitis Rheum. 2008;59(2):214-221.
158. Carroll CL, Lang W, Snively B, Feldman SR, Callen J, Jorizzo JL. Development and validation of the Dermatomyositis Skin Severity Index. Br J Dermatol. 2008;158(2):345-350.
159. Klein RQ, Bangert CA, Costner M, et al. Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis. Br J Dermatol. 2008;159(4):887-894.
160. Harris-Love MO, Shrader JA, Koziol D, et al. Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis. Rheumatology (Oxford). 2009;48(2):134-139.
161. Medical Research Council (Great Britain). Aids to the Examination of the Peripheral Nervous System. London: H. M. Stationary Off; 1976.
162. Fries JF, Spitz P, Kraines G, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137-145.
163. Alexanderson H, Lundberg IE, Stenström CH. Development of the Myositis Activities Profiledvalidity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol. 2002;29(11):2386-2392.
164. Alexanderson H, Reed AM, Ytterberg SR. The Myositis Activities Profiledinitial validation for assessment of polymyositis/ dermatomyositis in the USA. J Rheumatol. 2012;39(11):2134-2141.
165. Alexanderson H, Broman L, Tollbäck A, Josefson A, Lundberg IE, Stenström CH. Functional Index-2: validity and reliability of a disease-specific measure of impairment in patients with polymyositis and
166. Josefson A, Romanus E, Carlsson J. A functional index in myositis. J Rheumatol. 1996;23(8):1380-1384.
167. Huber AM, Feldman BM, Rennebohm RM, et al Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies. Arthritis Rheum. 2004;50(5):1595-1603.
168. Lovell DJ, Lindsley CB, Rennebohm RM, et al. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II: The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function; The Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Arthritis Rheum. 1999;42(10):2213-2219.
169. Huber AM, Hicks JE, Lachenbruch PA, et al Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Validation of the Childhood Health Assessment Questonnaire in the juvenile idiopathic myopathies: Juvenile Dermatomyositis Disease Activity Collaborative Study Group. J Rheumatol. 2001;28(5):1106-1111.
170. Jackson CE, Barohn RJ, Gronseth G, Pandya S, Herbelin L; Muscle Study Group. Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity. Muscle Nerve. 2008;37(4):473-476.
171. ALS CNTF Treatment Study (ACTS) Phase I-II Study Group. The Amyotrophic Lateral Sclerosis Functional Rating Scale: assessment of activities of daily living in patients with amyotrophic lateral sclerosis. Arch Neurol. 1996;53(2):141-147.
172. Cederbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function; BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1-2):13-21.
173. Nader GA, Lundberg IE. Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle. Curr Opin Rheumatol. 2009;21(6):599-603.
174. Alexanderson H, Dastmalchi M, Esbjörnsson-Liljedahl M, Opava CH, Lundberg IE. Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis. Arthritis Rheum. 2007;57(5):768-777.
175. Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis. 2000;59(suppl 1):i21-i27.
176. Scuderi F, Mannella F, Marino M, Provenzano C, Bartoccioni E. IL-6-deficient mice show impaired inflammatory response in a model of myosin-induced experimental myositis. J Neuroimmunol. 2006;176(1-2):9-15.
177. Baechler EC, Gregersen PK, Behrens TW. The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol. 2004;16(6):801-807.
178. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006;54(2):408-420.
179. Griffin TA, Reed AM. Pathogenesis of myositis in children. Curr Opin Rheumatol. 2007;19(5):487-491.
180. Stamp LK, Hurst M. Is there a role for consensus guidelines for P. jiroveci pneumonia prophylaxis in immunosuppressed patients with rheumatic diseases? J Rheumatol. 2010;37(4):686-688.
181. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007;82(9):1052-1059.
182. Ponyi A, Borgulya G, Constantin T, Váncsa A, Gergely L, Dankó K. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis. Rheumatology (Oxford). 2005;44(1):83-88.
183. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
184. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.